NVCT vs AURA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
NVCT · Nuvectis Pharma$19.39 ▼ 2.27%
AURA · Aura Biosciences$6.87 ▼ 1.58%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- NVCT +223.7%
- AURA +24.9%
Head to head
| Metric | NVCT | AURA |
|---|---|---|
| Price | $19.39 | $6.87 |
| Change today | ▼ 2.27% | ▼ 1.58% |
| Market cap | $666.80M | $714.99M |
| Return, 3 months | -18.8% | -13.0% |
| Return, year to date | +156.8% | +26.1% |
| Return, 1 year | +218.9% | +26.3% |
| P/E (TTM) | – | – |
| P/B | 5.3 | 2.5 |
| P/E percentile vs own 5y | 22nd | 46th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -303.0% | -22.7% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -67.0% | -61.7% |
| Analyst target vs. price | +77.9% | +162.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 47 | 51 |
| 30-day volatility | 78.4% | 64.9% |
| Max drawdown, 1 year | -37.7% | -32.6% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AURA is the largest of the group by market value.
- NVCT has returned the most over the past year.
- AURA has been the calmest stock over the last 30 days.